4//SEC Filing
FLEMING JONATHAN 4
Accession 0001012975-09-000005
CIK 0001062216other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 5:43 PM ET
Size
21.8 KB
Accession
0001012975-09-000005
Insider Transaction Report
Form 4
FLEMING JONATHAN
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2009-01-05−10,000→ 0 totalExercise: $0.41Exp: 2018-06-12→ Common Stock (10,000 underlying) - Disposition from Tender
Common Stock
2009-01-01$0.61/sh−267,844$163,385→ 0 total(indirect: By Partnership) - Disposition from Tender
Common Stock
2009-01-01$0.61/sh−3,595,503$2,193,257→ 0 total(indirect: By Oxford Bioscience Partners IV L.P.) - Disposition from Tender
Common Stock
2009-01-01$0.61/sh−36,076$22,006→ 0 total(indirect: By mRNA Fund II L.P.) - Disposition from Tender
Common Stock
2009-01-01$0.61/sh−357,715$218,206→ 0 total(indirect: By Oxford Bioscience Partners II L.P.) - Disposition from Tender
Common Stock
2009-01-01$0.61/sh−100,306$61,187→ 0 total(indirect: By Oxford Bioscience Partners (Adjunct) II L.P.) - Disposition from Tender
Common Stock
2009-01-01$0.61/sh−352,679$215,134→ 0 total(indirect: By Oxford Bioscience Partners (GS-Adjunct) II L.P.) - Disposition from Tender
Common Stock
2009-01-01$0.61/sh−1,283,317$782,823→ 0 total(indirect: By Oxford Bioscience Partners II (Annex) L.P.)
Footnotes (8)
- [F1]Securities held of record by Oxford Bioscience Partners IV L.P. ("Oxford"). Jonathan Fleming ("Fleming") is a general partner of the sole general partner of Oxford. Fleming expressly disclaims beneficial ownership of all shares held of record by Oxford, except to the extent of his actual pecuniary interest therein.
- [F2]Securities held of record by mRNA Fund II L.P. ("mRNA II"). Fleming is a general partner of the sole general partner of mRNA II. Fleming expressly disclaims beneficial ownership of all shares held of record by mRNA II, except to the extent of his actual pecuniary interest therein.
- [F3]Securities held of record by Oxford Bioscience Partners II L.P. ("Oxford II"). Fleming is a general partner of the sole general partner of Oxford II. Fleming expressly disclaims beneficial ownership of all shares held of record by Oxford II, except to the extent of his actual pecuniary interest therein.
- [F4]Securities held of record by Oxford Bioscience Partners (Adjunct) II L.P. ("Oxford Adjunct II"). Fleming is a general partner of the sole general partner of Oxford Adjunct II. Fleming expressly disclaims beneficial ownership of all shares held of record by Oxford Adjunct II, except to the extent of his actual pecuniary interest therein.
- [F5]Securities held of record by Oxford Bioscience Partners (GS-Adjunct) II L.P. ("Oxford GS-Adjunct II"). Fleming is a general partner of the sole general partner of Oxford GS-Adjunct II. Fleming expressly disclaims beneficial ownership of all shares held of record by Oxford GS-Adjunct II, except to the extent of his actual pecuniary interest therein.
- [F6]Securities held of record by Oxford Bioscience Partners II (Annex) L.P. ("Oxford II Annex"). Fleming is a general partner of the sole general partner of Oxford II Annex. Fleming expressly disclaims beneficial ownership of all shares held of record by Oxford II Annex, except to the extent of his actual pecuniary interest therein.
- [F7]Securities held of record by Oxford Bioscience Partners (Bermuda) II Limited Partnership ("Oxford Bermuda II"). Fleming is a general partner of the sole general partner of Oxford Bermuda II. Fleming expressly disclaims beneficial ownership of all shares held of record by Oxford Bermuda II, except to the extent of his actual pecuniary interest therein.
- [F8]This option, which provided for vesting in full on the first anniversary of the grant date, was canceled in connection with the Issuer's merger with 900 North Point Acquisition Corporation on January 5, 2009. In exchange, Fleming received a cash payment of $2,000, which represents the difference between the exercise price of the option and the offer price of $0.61 per share multiplied by the number of shares underlying the option.
Documents
Issuer
MEMORY PHARMACEUTICALS CORP
CIK 0001062216
Entity typeother
Related Parties
1- filerCIK 0001262294
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 5:43 PM ET
- Size
- 21.8 KB